Novel Targets for Alzheimer’s Disease Treatment: Medin and PLD3
Nina Culum2023-03-27T14:52:16-04:00News, Scientific Articles|
Given that Alzheimer's disease is multifactorial and heterogenous, drug development progress is more likely to occur if multiple pathways are considered. Two recent Nature publications have potentially identified medin and PLD3 as new targets for Alzheimer’s disease treatment, which we summarize in this mini-review.
Featured Webinars
Cut and Paste of Myosin Binding Protein-C in Striated Muscles
Tuesday, October 3, 2023
Sponsor: Aurora Scientific, Inc.
Partner: American Physiological Society
Evaluation of Novel Therapies Using Spontaneous Seizure Models
Wednesday, October 4, 2023
Sponsor: ADInstruments
Partners: American Physiological Society, Society for Neuroscience, Federation of European Neuroscience Societies, American Autonomic Society, Scientist.com
Turning Innovative Features Into Practical Benefits Within the Buxco Nose-Only Rodent Inhalation System
Thursday, September 28, 2023
Sponsors: Data Sciences International, Harvard Bioscience, Inc.
Advertisement
Latest News & Resources
The Sweet Truth: Unwrapping the Science of Semaglutide
August 9, 2023
Taurine: An Unexpected Anti-Aging Ally
July 18, 2023
Content Categories
Aging
Analytical Sciences
Animal Behavioral Neuroscience
Auditory Sciences
Cancer & Oncology Research
Cardiovascular
Cell & Molecular Biology
Clinical Research
Drug Discovery & Development
Education & Teaching
Epidemiology & Infectious Disease
General Biology
Genetics & Genomics
Human Physiology
Industry & Career
Lab Animal Sciences
Materials Science
Metabolic Function
Microbiology & Immunology
Microscopy
Muscle Physiology & Function
Neuroscience
Obesity
Pharmacology
Preclinical Imaging
Renal Physiology
Respiratory Science
Sports Science
Toxicology
Value, Evidence, Access
Vascular Biology
Vision Research